The MTMR14 Gene Centronuclear Myopathy Type 1 Genetic Test is a specialized diagnostic tool designed to detect mutations in the MTMR14 gene, which are linked to the development of Centronuclear Myopathy Type 1 (CNM1). CNM1 is a rare genetic disorder characterized by muscle weakness, decreased muscle tone, and potential respiratory complications, with symptoms often appearing from birth or early childhood. The test is aimed at individuals who exhibit symptoms of CNM1 or have a family history of the condition, providing crucial information for accurate diagnosis and management.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed to identify any genetic alterations in the MTMR14 gene. The results from this test can help guide treatment decisions, inform family planning, and provide a prognosis for affected individuals.
The cost of the MTMR14 Gene Centronuclear Myopathy Type 1 Genetic Test at DNA Labs UAE is 4400 AED. This cost reflects the specialized nature of the test, the expertise required to accurately interpret the results, and the comprehensive support provided to patients and families throughout the testing process.
The BIN1 Gene Centronuclear Myopathy Type 2 Genetic Test is a specialized diagnostic procedure designed to identify mutations in the BIN1 gene, which are linked to the development of Centronuclear Myopathy Type 2, a rare genetic disorder characterized by muscle weakness and structural abnormalities in muscle cells. This condition is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.
Performed at DNA Labs UAE, this genetic test involves analyzing the patient's DNA, extracted from a blood sample or cheek swab, to look for specific mutations in the BIN1 gene that are known to cause the disease. The test is crucial for confirming the diagnosis, understanding the disease's progression, and guiding treatment decisions. It can also provide valuable information for family planning and genetic counseling for families affected by Centronuclear Myopathy Type 2.
The cost of the BIN1 Gene Centronuclear Myopathy Type 2 Genetic Test at DNA Labs UAE is 4400 AED. Given the complexity of the test and the expertise required to interpret the results accurately, this price reflects the specialized nature of the genetic testing process. Patients considering this test are advised to consult with a genetic counselor or a healthcare provider specializing in genetic disorders to discuss the implications of the test results and the next steps in the management of the condition.
The MYF6 gene plays a crucial role in muscle development and function. Mutations in the MYF6 gene can lead to a rare genetic disorder known as Centronuclear Myopathy Type 3 (CNM3), characterized by muscle weakness and structural abnormalities in muscle cells. Identifying mutations in the MYF6 gene is essential for diagnosing CNM3, enabling early intervention and management of the condition.
DNA Labs UAE offers a specialized genetic test aimed at detecting mutations in the MYF6 gene associated with Centronuclear Myopathy Type 3. This test is a vital tool for individuals with a family history of CNM3 or those exhibiting symptoms consistent with the disorder. By analyzing the genetic material with precision, the test can confirm or rule out the presence of the specific mutations linked to this form of myopathy.
The cost of the MYF6 Gene Centronuclear Myopathy Type 3 Genetic Test at DNA Labs UAE is 4400 AED. The testing process involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory using advanced genetic sequencing techniques. The results provide valuable information for affected individuals and their families, guiding treatment decisions and genetic counseling.
It's important for potential test-takers to consult with a healthcare professional or genetic counselor before and after the test to understand the implications of the results and to receive appropriate support and guidance.
The CCDC78 gene centronuclear myopathy type 4 genetic test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the CCDC78 gene, which are linked to the development of centronuclear myopathy type 4 (CNM4). This condition is a rare genetic disorder characterized by muscle weakness and abnormalities in the placement of nuclei within muscle cells. The test plays a crucial role in the early detection and management of the disease, offering insights that can guide treatment options and genetic counseling.
The process involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory for the presence of specific genetic alterations in the CCDC78 gene. This test is particularly valuable for individuals with a family history of centronuclear myopathy or those exhibiting symptoms related to the condition, enabling them to make informed decisions regarding their health and family planning.
The cost of the CCDC78 gene centronuclear myopathy type 4 genetic test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to accurately identify the genetic mutation associated with the condition, offering peace of mind and a clear path forward for affected individuals and their families.
The SPEG Gene Centronuclear Myopathy Type 5 Genetic Test is a highly specialized diagnostic tool designed to identify mutations in the SPEG gene, which are linked to Centronuclear Myopathy Type 5 (CNM5). This condition is a rare genetic disorder characterized by muscle weakness and abnormalities in the placement of nuclei within muscle cells, leading to significant motor function impairment. Early detection through this genetic test is crucial for managing symptoms and planning treatment strategies.
The test is conducted at DNA Labs UAE, a leading facility in genetic diagnostics, ensuring high accuracy and reliability of results. The cost of the test is set at 4400 AED, reflecting the comprehensive analysis and detailed reporting provided. Through this test, individuals at risk or showing symptoms of CNM5 can gain valuable insights into their genetic makeup, allowing for informed medical and lifestyle decisions.
The CP Gene Cerebellar Ataxia Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the CP gene that are associated with the development of cerebellar ataxia. Cerebellar ataxia is a neurological disorder characterized by a lack of muscle coordination, which can affect speech, eye movements, the ability to swallow, walking, and other voluntary movements. This condition is often inherited and can be caused by mutations in various genes, including the CP gene.
The test is conducted through a comprehensive analysis of the patient's DNA, extracted from a blood sample, to detect specific genetic alterations in the CP gene that are known to contribute to the condition. The results from this test can provide crucial information for the diagnosis, management, and understanding of the individual's condition. It can also offer insights into the risk of passing the condition on to future generations, aiding in family planning decisions.
Priced at 4400 AED, the CP Gene Cerebellar Ataxia Genetic Test at DNA Labs UAE represents a significant investment in personal health and genetic understanding. It is a valuable resource for individuals showing symptoms of cerebellar ataxia or those with a family history of the disorder, offering them a clearer picture of their genetic health and enabling them to take informed steps towards managing their condition.
The "CA8 Gene Cerebellar Ataxia and Mental Retardation with or without Quadrupedal Locomotion Type 3 Genetic Test" is a specialized diagnostic tool offered by DNA Labs UAE, aimed at identifying mutations in the CA8 gene. These mutations are associated with a rare neurological disorder that can manifest as cerebellar ataxia, mental retardation, and in some cases, an unusual pattern of movement that may include quadrupedal locomotion. Cerebellar ataxia refers to a lack of muscle control or coordination of voluntary movements, which stems from problems in the cerebellum, the part of the brain that controls muscle coordination.
The test, priced at 4400 AED, involves analyzing the patient's DNA to detect abnormalities in the CA8 gene that could confirm the diagnosis of this condition. This genetic testing is crucial for families seeking to understand the genetic basis of the disorder, which can aid in managing the condition, anticipating its progression, and making informed decisions about care. Additionally, it can provide essential information for genetic counseling, especially for those planning to have children and concerned about passing on genetic conditions.
DNA Labs UAE, a leading facility in genetic testing, employs advanced technologies and methodologies to ensure accurate and reliable results. The test is conducted under the strictest standards of quality and confidentiality, ensuring that patients receive comprehensive support throughout the testing process.
The DNMT1 Gene Cerebellar Ataxia with Deafness and Narcolepsy Autosomal Recessive Genetic Test is a specialized diagnostic examination available at DNA Labs UAE, designed to identify mutations in the DNMT1 gene that are associated with a rare, autosomal recessive disorder. This condition is characterized by a combination of symptoms including cerebellar ataxia, which involves coordination and balance problems due to cerebellum damage; deafness; and narcolepsy, a chronic sleep disorder that causes overwhelming daytime drowsiness and sudden sleep attacks. The test is crucial for individuals who exhibit these symptoms or have a family history of the disorder, as it aids in the accurate diagnosis and management of the condition. The cost of the test is 4400 AED, reflecting the comprehensive analysis and expertise required to interpret the genetic data. Conducted at DNA Labs UAE, a leading facility in genetic testing, this test offers hope for affected individuals and their families by providing essential information for treatment planning and genetic counseling.
The WDR81 gene cerebellar ataxia with mental retardation and dysequilibrium syndrome type 2 genetic test is a specialized diagnostic tool available at DNA Labs UAE. This test is designed to identify mutations in the WDR81 gene, which are known to cause cerebellar ataxia with mental retardation and dysequilibrium syndrome type 2 (CAMRQ2). CAMRQ2 is a rare genetic disorder characterized by developmental delays, intellectual disability, and difficulties with coordination and balance due to cerebellar ataxia. The test is crucial for early diagnosis and management of the condition, offering insights that can guide therapeutic interventions and support. Priced at 4400 AED, the test involves analyzing the patient's DNA to detect abnormalities in the WDR81 gene, providing families and healthcare professionals with essential information for care planning and genetic counseling.
The "GBA2 Gene Cerebellar Ataxia with Spasticity Genetic Test" is a specialized diagnostic procedure aimed at individuals who exhibit symptoms of cerebellar ataxia combined with spasticity, suggesting a potential genetic underpinning. This test specifically targets the GBA2 gene, which has been linked to this neurological condition. Mutations in the GBA2 gene can disrupt normal brain function, leading to the symptoms observed in affected individuals. The test is designed to detect such mutations, providing crucial information for diagnosis, management, and treatment planning.
Conducted at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities, the test is available for a cost of 4400 AED. DNA Labs UAE employs state-of-the-art technology and methodologies to ensure accurate and reliable results, making it a preferred choice for genetic testing in the region. By opting for this test, patients and their families can gain insights into the genetic basis of the condition, facilitating informed decisions regarding healthcare and potential therapeutic interventions.
